News >

Therapies Moving Though Pipeline for Rare Mutations in NSCLC

Caroline Seymour
Published: Thursday, May 23, 2019

Dr. Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou, MD, PhD

In non–small cell lung cancer (NSCLC), KRAS G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1 fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication